PURPOSE: The radiolanthanide (161)Tb (T 1/2 = 6.90 days, Eβ(-) av = 154 keV) was recently proposed as a potential alternative to (177)Lu (T 1/2 = 6.71 days, Eβ(-) av = 134 keV) due to similar physical decay characteristics but additional conversion and Auger electrons that may enhance the therapeutic efficacy. The goal of this study was to compare (161)Tb and (177)Lu in vitro and in vivo using a tumour-targeted DOTA-folate conjugate (cm09). METHODS: (161)Tb-cm09 and (177)Lu-cm09 were tested in vitro on folate receptor (FR)-positive KB and IGROV-1 cancer cells using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) viability assay. In vivo (161)Tb-cm09 and (177)Lu-cm09 (10 MBq, 0.5 nmol) were investigated in two different tumour mouse models with regard to the biodistribution, the possibility for single photon emission computed tomography (SPECT) imaging and the antitumour efficacy. Potentially undesired side effects were monitored over 6 months by determination of plasma parameters and examination of kidney function with quantitative SPECT using (99m)Tc-dimercaptosuccinic acid (DMSA). RESULTS: To obtain half-maximal inhibition of tumour cell viability a 4.5-fold (KB) and 1.7-fold (IGROV-1) lower radioactivity concentration was required for (161)Tb-cm09 (IC50 ~0.014 MBq/ml and ~2.53 MBq/ml) compared to (177)Lu-cm09 (IC50 ~0.063 MBq/ml and ~4.52 MBq/ml). SPECT imaging visualized tumours of mice with both radioconjugates. However, in therapy studies (161)Tb-cm09 reduced tumour growth more efficiently than (177)Lu-cm09. These findings were in line with the higher absorbed tumour dose for (161)Tb-cm09 (3.3 Gy/MBq) compared to (177)Lu-cm09 (2.4 Gy/MBq). None of the monitored parameters indicated signs of impaired kidney function over the whole time period of investigation after injection of the radiofolates. CONCLUSION: Compared to (177)Lu-cm09 we demonstrated equal imaging features for (161)Tb-cm09 but an increased therapeutic efficacy for (161)Tb-cm09 in both tumour cell lines in vitro and in vivo. Further preclinical studies using other tumour-targeting radioconjugates are clearly necessary to draw final conclusions about the future clinical perspectives of (161)Tb.
PURPOSE: The radiolanthanide (161)Tb (T 1/2 = 6.90 days, Eβ(-) av = 154 keV) was recently proposed as a potential alternative to (177)Lu (T 1/2 = 6.71 days, Eβ(-) av = 134 keV) due to similar physical decay characteristics but additional conversion and Auger electrons that may enhance the therapeutic efficacy. The goal of this study was to compare (161)Tb and (177)Lu in vitro and in vivo using a tumour-targeted DOTA-folate conjugate (cm09). METHODS: (161)Tb-cm09 and (177)Lu-cm09 were tested in vitro on folate receptor (FR)-positive KB and IGROV-1 cancer cells using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) viability assay. In vivo (161)Tb-cm09 and (177)Lu-cm09 (10 MBq, 0.5 nmol) were investigated in two different tumourmouse models with regard to the biodistribution, the possibility for single photon emission computed tomography (SPECT) imaging and the antitumour efficacy. Potentially undesired side effects were monitored over 6 months by determination of plasma parameters and examination of kidney function with quantitative SPECT using (99m)Tc-dimercaptosuccinic acid (DMSA). RESULTS: To obtain half-maximal inhibition of tumour cell viability a 4.5-fold (KB) and 1.7-fold (IGROV-1) lower radioactivity concentration was required for (161)Tb-cm09 (IC50 ~0.014 MBq/ml and ~2.53 MBq/ml) compared to (177)Lu-cm09 (IC50 ~0.063 MBq/ml and ~4.52 MBq/ml). SPECT imaging visualized tumours of mice with both radioconjugates. However, in therapy studies (161)Tb-cm09 reduced tumour growth more efficiently than (177)Lu-cm09. These findings were in line with the higher absorbed tumour dose for (161)Tb-cm09 (3.3 Gy/MBq) compared to (177)Lu-cm09 (2.4 Gy/MBq). None of the monitored parameters indicated signs of impaired kidney function over the whole time period of investigation after injection of the radiofolates. CONCLUSION: Compared to (177)Lu-cm09 we demonstrated equal imaging features for (161)Tb-cm09 but an increased therapeutic efficacy for (161)Tb-cm09 in both tumour cell lines in vitro and in vivo. Further preclinical studies using other tumour-targeting radioconjugates are clearly necessary to draw final conclusions about the future clinical perspectives of (161)Tb.
Authors: Roelf Valkema; Stanislas A Pauwels; Larry K Kvols; Dik J Kwekkeboom; Francois Jamar; Marion de Jong; Raffaella Barone; Stephan Walrand; Peter P M Kooij; Willem H Bakker; Janet Lasher; Eric P Krenning Journal: J Nucl Med Date: 2005-01 Impact factor: 10.057
Authors: Dik J Kwekkeboom; Wouter W de Herder; Boen L Kam; Casper H van Eijck; Martijn van Essen; Peter P Kooij; Richard A Feelders; Maarten O van Aken; Eric P Krenning Journal: J Clin Oncol Date: 2008-05-01 Impact factor: 44.544
Authors: Edgar J Rolleman; Marleen Melis; Roelf Valkema; Otto C Boerman; Eric P Krenning; Marion de Jong Journal: Eur J Nucl Med Mol Imaging Date: 2009-11-14 Impact factor: 9.236
Authors: M de Jong; W A Breeman; B F Bernard; E J Rolleman; L J Hofland; T J Visser; B Setyono-Han; W H Bakker; M E van der Pluijm; E P Krenning Journal: Eur J Nucl Med Date: 1995-07
Authors: Richard P Baum; Aviral Singh; Harshad R Kulkarni; Peter Bernhardt; Tobias Rydén; Christiane Schuchardt; Nadezda Gracheva; Pascal V Grundler; Ulli Köster; Dirk Müller; Michael Pröhl; Jan Rijn Zeevaart; Roger Schibli; Nicholas P van der Meulen; Cristina Müller Journal: J Nucl Med Date: 2021-02-05 Impact factor: 10.057
Authors: Peter Bernhardt; Johanna Svensson; Jens Hemmingsson; Nicholas P van der Meulen; Jan Rijn Zeevaart; Mark W Konijnenberg; Cristina Müller; Jon Kindblom Journal: Cancers (Basel) Date: 2021-04-22 Impact factor: 6.639
Authors: Francesca Borgna; Stephanie Haller; Josep M Monné Rodriguez; Mihaela Ginj; Pascal V Grundler; Jan Rijn Zeevaart; Ulli Köster; Roger Schibli; Nicholas P van der Meulen; Cristina Müller Journal: Eur J Nucl Med Mol Imaging Date: 2021-10-08 Impact factor: 9.236
Authors: Cristina Müller; Christiaan Vermeulen; Karl Johnston; Ulli Köster; Raffaella Schmid; Andreas Türler; Nicholas P van der Meulen Journal: EJNMMI Res Date: 2016-04-23 Impact factor: 3.138
Authors: Stephanie Haller; Giovanni Pellegrini; Christiaan Vermeulen; Nicholas P van der Meulen; Ulli Köster; Peter Bernhardt; Roger Schibli; Cristina Müller Journal: EJNMMI Res Date: 2016-02-09 Impact factor: 3.138
Authors: Gregory W Severin; Lotte K Kristensen; Carsten H Nielsen; Jesper Fonslet; Andreas I Jensen; Anders F Frellsen; K M Jensen; Dennis R Elema; Helmut Maecke; Andreas Kjær; Karl Johnston; Ulli Köster Journal: Front Med (Lausanne) Date: 2017-07-12
Authors: Katharina A Domnanich; Cristina Müller; Martina Benešová; Rugard Dressler; Stephanie Haller; Ulli Köster; Bernard Ponsard; Roger Schibli; Andreas Türler; Nicholas P van der Meulen Journal: EJNMMI Radiopharm Chem Date: 2017-06-02